ArticleMethods in molecular biology (Clifton, N.J.)2026
Micro RNA Sequencing in Circulating Tumor Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) play a crucial role in the analysis of circulating tumor cells (CTCs) due to their unique properties and involvement in cancer biology. miRNAs in CTCs can help to identify early changes associated with metastasis, allowing for early intervention. Specific miRNAs are associated with drug resistance mechanisms, and their presence or absence in CTCs can help predict the effectiveness of treatment options, enabling personalized therapy adjustments. Changes in miRNA expression levels in CTCs can also be used to monitor disease progression or detect early signs of recurrence after treatment. This is especially important in managing cancers that are prone to relapse. Therefore, the in-depth characterization of physiological miRNA functions is an important basic research question, and miRNAs even have a high potential as biomarkers both for prognosis and diagnosis. To exploit this potential, it is mandatory to accurately quantify the miRNA expression not only in tumor bulk, but also on the single CTC level. Here, we describe a protocol that facilitates miRNA sequencing library preparation in CTCs. The protocol can be combined with different single-cell isolation methods (e.g., micromanipulation and FACS sorting). After cell lysis, sequencing adapters are ligated to the miRNAs, other ncRNA species and adapter dimers are reduced by exonuclease digest, the miRNA library is reverse transcribed, amplified and purified. Furthermore, quality controls are described to select only high-quality samples for sequencing.
Indexed as
Identifiers
42426461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.